My watch list  


Biolex Therapeutics is a biotechnology firm in the Research Triangle of North Carolina. The company focuses on formation of difficult to synthesize proteins in Lemna, a duckweed.[1] The duckweeds are a family of small aquatic plants that can be grown in sterile culture. Biolex has developed recombinant DNA technology for efficiently producing pharmaceutical proteins in Lemna.[2] Therapeutic glycosylated proteins, such as monoclonal antibodies, have been produced by the Lemna system at Biolex.[3]

Biolex acquired Epicyte Pharmaceutical Inc. on May 6, 2004, and acquired LemnaGene SA of Lyon, France in 2005.[4] Biolex is a privately held company backed by Quaker BioVentures, The Trelys Funds, and Polaris Venture Partners. The term "plantibody" is trademarked by Biolex.


  • Official site
  • Background information on production of therapeutic proteins in 'Lemna'
  1. ^ Goodman Peter S. In N.C., A Second Industrial Revolution: Biotech Surge Shows Manufacturing Still Key to U.S. Economy [1] Washington Post Monday, September 3, 2007
  2. ^ John R. Gasdaska, David Spencer and Lynn Dickey "Advantages of Therapeutic Protein Production in the Aquatic Plant Lemna" BioProcessing Journal, Mar/Apr 2003.
  3. ^ Cox KM et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol. 2006 Dec;24(12):1591-7.
  4. ^ Biolex Therapeutics Acquires Lemnagene S.A.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Biolex". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE